

75% by weight of the composition together with a liquid binding agent comprising a saccharide having high moldability, and

(b) a step of blending with the celecoxib a saccharide having low moldability, wherein steps (a) and (b) occur in any order or simultaneously to result in formation of granules, and wherein the process incorporates means to inhibit agglomeration of the celecoxib.

14. The process of Claim 1 wherein said means to inhibit agglomeration comprises pre-wetting the celecoxib prior to said step (a).

15. The process of Claim 1 wherein said means to inhibit agglomeration of the celecoxib comprises addition of a wetting agent.

28. The process of Claim 1 wherein the celecoxib is present in an amount of about 30% to about 75% by weight of the composition.

29. The process of Claim 1 wherein the celecoxib is present in an amount of about 45% to about 75% by weight of the composition.

42. An oral fast-melt composition comprising celecoxib in an amount of about 15% to about 75% by weight of the composition, uniformly dispersed in a matrix comprising a saccharide of low moldability and a saccharide of high moldability.

62. The composition of Claim 42 wherein the celecoxib is present in an amount of about 30% to about 75% by weight of the composition.

63. The composition of Claim 42 wherein the celecoxib is present in an amount of about 45% to about 75% by weight of the composition.

REMARKS

By the present amendment, eighteen (18) claims are cancelled, and eight (8) claims including two (2) independent claims are amended. No additional claim fees are payable.

The present amendment is proposed in part to simplify issues in prosecution by focusing the claims on a presently preferred embodiment of the invention wherein the selective cyclooxygenase-2 (COX-2) inhibitory drug is celecoxib and is present in an amount of about 15% to about 75% of the composition. Applicant reserves the right to reintroduce subject matter voluntarily cancelled herein in one or more later continuation or divisional applications.

Claims 4-7, 9, 54-57, 59, 84 and 85 are cancelled as they embrace selective COX-2